Drug intelligence / Profile preview

JB-201

Development stage: Preclinical
Lead developer: Junten Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

JB-201 is a preclinical antibody drug under development by Junten Bio for the prevention of graft rejection in patients undergoing kidney transplantation from brain-dead donors. While Junten Bio is primarily known for its Induced Suppressor T cells (JB-101) platform, JB-201 represents a separate antibody-based therapeutic approach aimed at improving outcomes in deceased-donor transplants. The drug is intended to modulate the immune response to induce tolerance and reduce the reliance on long-term immunosuppressive therapy, although its specific molecular target and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on JB-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JB-201.

Explore the full profile